<DOC>
	<DOCNO>NCT02525874</DOCNO>
	<brief_summary>The primary objective study evaluate effect BG00012 lymphocyte subset count first year treatment subject relapsing-remitting multiple sclerosis ( RRMS ) . A secondary objective evaluate pharmacodynamic effect absolute lymphocyte count ( ALCs ) immunoglobulins ( Igs ) first year treatment .</brief_summary>
	<brief_title>Effect BG00012 Lymphocyte Subsets Immunoglobulins Subjects With Relapsing Remitting Multiple Sclerosis ( RRMS ) .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Subjects childbearing potential ( include female subject postmenopausal less 1 year ) must practice effective contraception study willing able continue contraception 30 day last dose study treatment . Must confirm diagnosis RRMS accord revise McDonald criterion ( 2010 ) [ Polman 2011 ] Key History positive test result Screening : human immunodeficiency virus hepatitis C virus antibody hepatitis B infection Drug alcohol abuse within 1 year prior Screening . Prior treatment follow : cladribine mitoxantrone total lymphoid irradiation alemtuzumab Tcell Tcell receptor vaccination therapeutic monoclonal antibody , exception natalizumab daclizumab Treatment follow medication procedure within 6 month prior Baseline ( Day 1 ) : DMF ( give FumadermÂ® ) BG00012 ; enrollment limit 40 subject ( 200 ) prior DMF exposure cyclosporine azathioprine methotrexate mycophenolate mofetil intravenous ( IV ) Ig plasmapheresis cytapheresis NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tecfidera</keyword>
	<keyword>DMF</keyword>
	<keyword>dimethyl fumarate</keyword>
</DOC>